Two European companies - the Belgian-Dutch biotech Argenx and Calliditas of Sweden - are going it alone to commercialize their just-approved rare disease therapies in the US.

Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.

As tightening policies cast a shadow over Chinese bioventures relying mainly on in-licensing and shed fresh light on the importance of proprietary development, the CEO of one innovation-focused venture shares his views on strategy in an exclusive interview.

Billed as BridgeBio in China, US-based and China-oriented biotech LianBio breaks a long hiatus in US listing for Chinese biotechs.